Key result
Sutureless AVR dominates TAVI with ~1.1 more QALYs and lower overall costs.
Why the study?
Transcatheter aortic valve implants and sutureless aortic valve replacement show differing effectiveness, safety, and surgical cost profiles, prompting an evaluation of their incremental cost-utility across six countries.
Does sutureless aortic valve replacement improve cost-utility compared to TAVI in intermediate- to high-risk patients?
Does sutureless aortic valve replacement improve cost-utility compared to TAVI in intermediate- to high-risk patients?
Sutureless aortic valve replacement is a dominant strategy (more effective and less costly) compared to TAVI in intermediate- to high-risk patients based on this simulation model.
Answers are grounded in this paper and cite their sources.
May support sutureless AVR preference over TAVI in intermediate- to high-risk patients; extends modeling data but leaves open RCT confirmation.
BACKGROUND: Meta-analyses of studies comparing transcatheter aortic valve implants (TAVIs) and sutureless aortic valve replacement (SU-AVR) show differing effectiveness and safety profiles. The approaches also differ in their surgical cost (including operating room and device). OBJECTIVE: The objective of this study was to assess the incremental cost-utility of SU-AVR vs TAVIs for the treatment of intermediate- to high-risk patients in the US, Germany, France, Italy, UK, and Australia. METHODS: A patient-level simulation compares in-hospital pathways of patients undergoing SU-AVR or TAVIs; later, patient history is modeled at the cohort level. Hospital outcomes for TAVIs reproduce data from recent series; in SU-AVR patients, outcomes are obtained by applying relative efficacy estimates in a recent meta-analysis on 1,462 patients. After discharge, survival depends on the development of paravalvular leak and the need for dialysis. A comprehensive third-party payer perspective encompassing both in-hospital and long-term costs was adopted. RESULTS: Due to lower in-hospital (4.1% vs 7.0%) and overall mortality, patients treated with SU-AVR are expected to live an average of 1.25 years more compared with those undergoing TAVIs, with a mean gain of 1.14 quality-adjusted life-years. Both in-hospital and long-term costs were lower for SU-AVR than for TAVIs with total savings ranging from $4,158 (France) to $20,930 (US). CONCLUSION: SU-AVR results dominant when compared to TAVIs in intermediate- to high-risk patients. Both in-hospital and long-term costs are lower for SU-AVR than for TAVI patients, with concomitant significant gains in life expectancy, both raw and adjusted for the quality of life.
No takes yet. Share an insight, caveat, or question.
Povero et al. (2018) studied Severe aortic stenosis (n=1,462). Sutureless aortic valve replacement (SU-AVR) using Perceval bioprosthesis vs. Transcatheter aortic valve implant (TAVI) was evaluated on Incremental cost-utility (Quality-Adjusted Life-Years [QALYs] and total costs) (MD 1.14 QALYs). Sutureless aortic valve replacement was dominant over TAVI, yielding +1.14 QALYs, +1.25 life-years, lower in-hospital mortality, and savings of $4,158 to $20,930.
Synapse has enriched 10 related papers. Consider them for comparative context: